University of Texas Texas AM Investment Managment Co. Decreases Holdings in Apollo Endosurgery Inc (APEN)

University of Texas Texas AM Investment Managment Co. trimmed its position in shares of Apollo Endosurgery Inc (NASDAQ:APEN) by 42.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,293 shares of the biotechnology company’s stock after selling 50,907 shares during the period. Apollo Endosurgery makes up about 0.2% of University of Texas Texas AM Investment Managment Co.’s holdings, making the stock its 11th largest holding. University of Texas Texas AM Investment Managment Co. owned about 0.39% of Apollo Endosurgery worth $477,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in APEN. Renaissance Technologies LLC acquired a new position in Apollo Endosurgery during the fourth quarter worth $126,000. Dimensional Fund Advisors LP acquired a new stake in shares of Apollo Endosurgery in the first quarter valued at $378,000. NJ State Employees Deferred Compensation Plan acquired a new stake in shares of Apollo Endosurgery in the first quarter valued at $959,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Apollo Endosurgery by 7.5% in the first quarter. Russell Investments Group Ltd. now owns 331,163 shares of the biotechnology company’s stock valued at $2,037,000 after acquiring an additional 23,128 shares in the last quarter. Institutional investors own 32.77% of the company’s stock.

Several analysts have recently issued reports on the company. ValuEngine upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Northland Securities cut Apollo Endosurgery from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 9th. Roth Capital reiterated a “neutral” rating and issued a $9.50 price objective on shares of Apollo Endosurgery in a research note on Tuesday, July 17th. Finally, Zacks Investment Research upgraded Apollo Endosurgery from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Apollo Endosurgery presently has a consensus rating of “Hold” and an average price target of $8.56.

Shares of NASDAQ APEN traded up $0.07 during mid-day trading on Thursday, hitting $7.63. The company had a trading volume of 100 shares, compared to its average volume of 52,117. The stock has a market cap of $169.56 million, a P/E ratio of -3.80 and a beta of 0.11. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.60. Apollo Endosurgery Inc has a 1-year low of $3.55 and a 1-year high of $9.65.

Apollo Endosurgery (NASDAQ:APEN) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The company had revenue of $15.79 million during the quarter, compared to analyst estimates of $16.56 million. Apollo Endosurgery had a negative net margin of 46.55% and a negative return on equity of 58.61%. equities analysts forecast that Apollo Endosurgery Inc will post -1.65 EPS for the current fiscal year.

In other Apollo Endosurgery news, Director Matthew S. Crawford bought 363,500 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The shares were purchased at an average price of $5.50 per share, with a total value of $1,999,250.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Todd Newton bought 72,727 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The stock was acquired at an average cost of $5.50 per share, for a total transaction of $399,998.50. Following the acquisition, the chief executive officer now directly owns 268,606 shares of the company’s stock, valued at $1,477,333. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 440,772 shares of company stock worth $2,424,246. Insiders own 52.80% of the company’s stock.

About Apollo Endosurgery

Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope.

See Also: Google Finance

Want to see what other hedge funds are holding APEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apollo Endosurgery Inc (NASDAQ:APEN).

Institutional Ownership by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply